ILMN240712C107000
- 11.14
- 0.000.00%
Illumina Newsroom
Should You Consider Adding Illumina (ILMN) to Your Portfolio?
$1000 Invested In Illumina 20 Years Ago Would Be Worth This Much Today
Illumina (NASDAQ:ILMN) has outperformed the market over the past 20 years by 12.43% on an annualized basis producing an average annual return of 20.85%. Currently, Illumina has a market
Illumina Ventures Adds Two New Experts as Advisors
Illumina to Present Upcoming Strategy Update
SAN DIEGO, July 18, 2024 /PRNewswire/ -- As Illumina, Inc. (NASDAQ: ILMN) previously announced on June 24, the company will present a Strategy Update on Tuesday, August 13, 2024 starting at 8:00am
NIH Outlays Rise by 5% in June, Says Baird
Super Micro Joins the Nasdaq 100. Walgreens Gets the Boot.
The change reflects the sharp decline in Walgreens' market value this year and the surge in Super Micro's stock price.
Here's How Much You Would Have Made Owning Illumina Stock In The Last 20 Years
Illumina (NASDAQ:ILMN) has outperformed the market over the past 20 years by 12.7% on an annualized basis producing an average annual return of 21.1%. Currently, Illumina has a market capitalization
These Are the Stocks With the Highest Increase in Short Interest Within Life Sciences and Diagnostics - Baird
Lilly, DaVita, Illumina Among Top Healthcare Quant Picks Ahead of Q2 Earnings
Illumina to Announce Second Quarter 2024 Financial Results on Tuesday, August 6, 2024
SAN DIEGO, July 11, 2024 /PRNewswire/ -- As Illumina, Inc. (NASDAQ:ILMN) previously announced on June 24, the company will issue results for the second quarter 2024 following the close of market on
Stephens Maintains Illumina(ILMN.US) With Buy Rating, Maintains Target Price $170
Stephens analyst Mason Carrico maintains $Illumina(ILMN.US)$ with a buy rating, and maintains the target price at $170.According to TipRanks data, the analyst has a success rate of 20.0% and a total
Citi Upgrades Illumina, Quest, Agilent to Buy, Downgrades Avantor
What's Going On With 10x Genomics Stock On Wednesday?
Wednesday, Illumina Inc (NASDAQ:ILMN) acquired Fluent BioSciences to expand its reach in single-cell analysis and multiomics research for an undisclosed consideration.Amid this M&A deal, 10x Genomics,
Illumina Buys Fluent BioSciences To Gain Stronger Foothold In Single-Cell Analysis
Last month, Illumina Inc (NASDAQ:ILMN) had to let go of Grail Inc. Still, the DNA sequencing company has acquired Fluent BioSciences to expand its reach in single-cell analysis and multiomics
Illumina Deal Sends 10x Genomics Stock Tumbling
Shares of 10x Genomics, which specializes in tools that allow scientists to precisely analyze the genes of a single cell at a time, were falling fast on Wednesday after a small
10x Genomics Stock Slides 14% Amid Illumina Deal, Deutsche Downgrade
SMART Global Posts Upbeat Results, Joins Aehr Test Systems, MarineMax And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were mostly higher, with the Nasdaq Composite gaining around 0.4% on Wednesday.Shares of SMART Global Holdings, Inc. (NASDAQ:SGH) rose sharply during Wednesday's session after the
Express News | Shares of Peer 10X Genomics Down 13.3%
Sector Update: Health Care Stocks Steady Premarket Wednesday
Health care stocks were steady premarket Wednesday as the Health Care Select Sector SPDR Fund (XLV) was up 0.03% and the iShares Biotechnology ETF (IBB) was recently inactive.Illumina (ILMN) rose 4%
Stephens & Co. Reiterates Overweight on Illumina, Maintains $170 Price Target
Stephens & Co. analyst Mason Carrico reiterates Illumina (NASDAQ:ILMN) with a Overweight and maintains $170 price target.